Year: 2023

Paris, November 14, 2023, 2 PM CET PRESS RELEASE Eramet inaugurates a pilot plant for the recycling of electric vehicle batteries Eramet is inaugurating a pilot plant at its Research & Innovation center close to Paris (Trappes) to test and optimize the production of battery-grade metal salts from black mass from recycled lithium-ion batteries. This facility is a 1:1,000 scale replica of the plant due to be built in Dunkirk (59), with start-up scheduled for 2027, subject to a final investment decision expected by the end of 2024. The creation of this pilot plant is a key stage for this project carried out in partnership with SUEZ and aiming to offer a closed-loop industrial recycling solution for end-of-life batteries and scrap from the production of new batteries. Thanks to its expertise in hydrometallurgy, Eramet’s Research &...

REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced it has initiated a process to explore strategic alternatives with the goal of maximizing shareholder value. While the Company has made progress developing the Talis One® system, it believes that this is a prudent path forward given current market conditions. As part of this process, the Company’s Board of Directors has appointed a special committee of independent, disinterested directors to consider a wide range of strategic alternatives, including, but not limited to, equity or debt financing alternatives, an acquisition, merger, reverse merger,...

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business UpdateAnnounced positive full 24-week data from the global Phase 2 MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for hidradenitis suppurativa Presented positive 12-week data from the global Phase 2 MIRA clinical trial for sonelokimab in hidradenitis suppurativa at a late-breaking session during the European Academy of Dermatology and Venereology Congress Announced landmark top-line 12-week data from the global Phase 2 ARGO clinical trial evaluating the efficacy and safety of sonelokimab in patients with active psoriatic arthritis, in support of a potential best-in-class profile Ended third quarter with $496.0 million in cash, cash equivalents and short-term marketable...

New Contract and Contract Renewal Momentum Continues BRENTWOOD, Tenn., Nov. 14, 2023 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (“CoreCivic”) announced today it signed a new management contract with the state of Montana for the housing of up to 120 inmates at the Company’s 1,896-bed Saguaro Correctional Facility in Eloy, Arizona.   The new management contract commences immediately and ends October 31, 2025. The contract may be extended by mutual agreement. The total term, including renewals, may not exceed seven years. We anticipate completing the receipt of the inmates from Montana at the Saguaro facility by December 31, 2023. Damon T. Hininger, President and Chief Executive Officer commented, “We are grateful for our longstanding partnership with the Montana Department of Corrections and honored by...

A corporate workshop session will feature Dr. Alka Chaubey, Bionano’s chief medical officer, Dr. Panieh Terraf from Memorial Sloan Kettering Cancer Center, Dr. Ravindra Kolhe from Augusta University, and Dr. Miriam Bornhorst from Children’s National Hospital presenting data on the role of structural variants (SVs) in central nervous system (CNS) tumor analysis conducted using optical genome mapping (OGM) A second corporate workshop session will feature Dr. Alex Hastie, Bionano’s vice president of clinical and scientific affairs, delivering an overview of the OGM workflow, followed by Drs. Scott Ryall and Adrian Dubuc from Brigham and Women’s Hospital and Dr. Susan Crocker from Kingston General Hospital Network presenting their data from studies conducted using OGM for hematological malignancy research. Dr. Adam Smith from the University...

– Received strategic investment from Sanofi purchasing $30 million of ordinary shares of the Company at a price of $7.50 per share in October 2023 – Announced a right of first negotiation (ROFN) with Sanofi for the use of MeiraGTx’s Riboswitch gene regulation technology for certain Central Nervous System (CNS) and Immunology and Inflammation (I&I) targets, including IL-4 and IL-13, as well as for GLP-1 and other gut peptides for metabolic disease, and for MeiraGTx’s Phase 2 Xerostomia program – Enrollment in the Phase 2 randomized, double-blind, placebo-controlled study of AAV2-hAQP1 for the treatment of grade 2/3 radiation-induced Xerostomia (RIX) is ongoing – Presented eight posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress including data on proprietary RiboCAR platform...